sur Immunic AG
Immunic Enrolls First Patient in Phase 2 Trial for Post COVID Syndrome
NEW YORK, September 4, 2024 – Immunic, Inc. (Nasdaq: IMUX) announced the enrollment of the first patient in a phase 2 clinical trial of vidofludimus calcium for Post COVID Syndrome (PCS). This trial, named RAPID_REVIVE, is sponsored by Goethe University Frankfurt and funded by the German government.
Vidofludimus calcium, Immunic's lead asset, is known for its antiviral and anti-inflammatory effects. The trial includes significant readouts on Epstein-Barr virus (EBV) reactivation, linked to fatigue, a common symptom in PCS and multiple sclerosis (MS) patients. Earlier studies showed the drug's potential in reducing fatigue in these conditions.
The RAPID_REVIVE trial will enroll 376 patients across 11 sites in Germany, with primary endpoints measuring physical function changes. Secondary endpoints will focus on mental and physical health, fatigue intensity, and cognitive function. Vidofludimus calcium aims to address these symptoms, providing hope for improved quality of life in PCS and MS patients.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Immunic AG